Ticagrelor

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Myocardial Infarction

Conditions

Myocardial Infarction

Trial Timeline

Oct 1, 2014 → Jan 1, 2016

NCT ID

NCT02292277

About Ticagrelor

Ticagrelor is a pre-clinical stage product being developed by AstraZeneca for Myocardial Infarction. The current trial status is completed. This product is registered under clinical trial identifier NCT02292277. Target conditions include Myocardial Infarction.

What happened to similar drugs?

20 of 20 similar drugs in Myocardial Infarction were approved

Approved (20) Terminated (3) Active (0)

✅AbciximabEli LillyApproved

✅abciximabEli LillyApproved

✅Ticagrelor + ClopidogrelAstraZenecaApproved

✅ticagrelor + aspirinAstraZenecaApproved

✅Ticagrelor + PlaceboAstraZenecaApproved

✅Ticagrelor 180mg loading dose taken orally, followed by 90mg twice daily (bd)AstraZenecaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03492931	Phase 1	Completed	Mar 28, 2018	May 7, 2019	Sickle Cell Disease
NCT03145194	Phase 2	UNKNOWN	Jan 30, 2017	Nov 30, 2019	ST Elevation Myocardial Infarction
NCT02341729	Approved	Completed	Mar 1, 2015	Dec 1, 2019	Acute Coronary Syndrome
NCT02292277	Pre-clinical	Completed	Oct 1, 2014	Jan 1, 2016	Myocardial Infarction
NCT02282332	Approved	Completed	Jun 1, 2014	Apr 1, 2016	Coronary Artery Disease
NCT02071212	Phase 2	Completed	Feb 1, 2014	Jun 1, 2018	Coronary Artery Disease
NCT01870921	Approved	Completed	Jun 26, 2013	Sep 30, 2015	Acute Coronary Syndrome

Competing Products

20 competing products in Myocardial Infarction

See all competitors

Product	Company	Stage	Hype Score
Butylphthalide + Butylphthalide placebo	CSPC Pharmaceutical Group Limited	Phase 3	47
Abciximab	Eli Lilly	Approved	43
Prasugrel + Clopidogrel	Daiichi Sankyo	Phase 3	40
Regadenoson + gadofoveset trisodium	Astellas Pharma	Phase 2	35
Half-dose of the Tc99-m sestamibi (Cardiolite)	Astellas Pharma	Pre-clinical	18
No intervention	Astellas Pharma	Pre-clinical	22
Empagliflozin + Placebo	Eli Lilly	Phase 3	40
Abciximab + Abciximab placebo	Eli Lilly	Phase 3	36
Intracoronary infusion of enriched bone marrow-derived progenitor cells + Placebo medium supplemented with autologous serum	Eli Lilly	Phase 3	40
Abciximab	Eli Lilly	Approved	43
abciximab placebo; reteplase placebo, abciximab, abciximab + Abciximab; reteplase; abciximab placebo; abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + abciximab placebo; reteplase placebo, abciximab, abciximab + abciximab; reteplase placebo; abciximab placebo; abciximab + Abciximab; reteplase; abciximab placebo; abciximab	Eli Lilly	Phase 3	40
fibrinolytic therapy or combination reduced fibrinolytic therapy	Eli Lilly	Phase 3	40
abciximab	Eli Lilly	Approved	43
tenecteplase + enoxaparin + clopidogrel	Eli Lilly	Phase 2/3	38
Thrombolytic therapy	Eli Lilly	Pre-clinical	22
Ticagrelor	AstraZeneca	Phase 2	31
Dual-antiplatelet therapy + Dual-antiplatelet therapy	AstraZeneca	Pre-clinical	22
Metoprolol- Toprol XL + Metoprolol- Lopressor	AstraZeneca	Phase 1	29
Ticagrelor orodispersible tablets + Ticagrelor standard tablets	AstraZeneca	Phase 3	40
Rosuvastatin	AstraZeneca	Phase 3	40